医学
中止
内科学
肺癌
克里唑蒂尼
临床终点
肿瘤科
人口
碱性抑制剂
一线治疗
铈替尼
临床试验
化疗
环境卫生
恶性胸腔积液
作者
David Heredia,Feliciano Barrón,Andrés Felipe Cardona,Saul Campos,Jerónimo Rafael Rodríguez-Cid,Luis Manuel Martínez-Barrera,Jorge Alatorre,Miguel Ángel Cruz Salinas,Luis Lara‐Mejía,Diana Flores‐Estrada,Óscar Arrieta
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-01-01
卷期号:17 (2): 169-181
被引量:5
标识
DOI:10.2217/fon-2020-0747
摘要
Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary end point was progression-free survival (PFS); secondary end point was time to treatment discontinuation (TTD). Results: At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6–18.8), and TTD was 18.46 months (95% CI: 9.54–27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data. Conclusion: Brigatinib is an effective treatment for previously treated ALK-positive NSCLC patients in a real-world setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI